Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Take part in our new study looking at flu vaccines

The Oxford Vaccine Group, part of the University of Oxford, would like to invite you and your child to take part in a study to investigate the immune response to a flu vaccine.

We are looking to enroll healthy Caucasian children aged 13 to 24 months, these children would receive two doses of a flu vaccine and three blood tests. Healthy Caucasian adults aged 18 to 65 years are also able to participate, they would receive one dose of a flu vaccine and four blood tests. We would use local anaesthetic cream on the skin to reduce any discomfort from the blood sampling.

You would have 24 hour telephone access to a paediatrician, should you have any concerns following vaccination. Taking part in this study is voluntary.

If you would like to any further information please visit:

Our website

You can also contact us by telephone on 01865 857420 or you can e-mail us at info@ovg.ox.ac.uk.

 

Similar stories

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19 Vaccinology

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Oxford University breakthrough on global COVID-19 vaccine

COVID-19 Vaccinology

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Oxford coronavirus vaccine produces strong immune response in older adults

COVID-19 Vaccinology

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

SIMON Says…

Vaccinology

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

Children’s pain ‘swept under the carpet for too long’ – Lancet Commission

Neuroimaging Publication Research

The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.

Coronavirus: the road to vaccine roll-out is always bumpy, as 20th-century pandemics show

COVID-19 Vaccinology

Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.